Cytokine polymorphisms and hepatocellular carcinoma

To B or not to B


  • Raymond T. Chung M.D.

    Corresponding author
    1. Gastrointestinal Unit, Massachusetts General Hospital, Boston, Massachusetts
    • Gastrointestinal Unit, GRJ 825, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114
    Search for more papers by this author
    • See referenced original article on pages 740–8, this issue.

  • Fax: (617) 726-5895


Regardless of whether monitoring practices change as a result of genotyping, the mandate that replicative hepatitis B virus disease must be treated because of the long-term risk for necroinflammatory disease, fibrosis, cirrhosis, and hepatocellular carcinoma remains firmly in place.

See also pages 740–8.